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Introduction: Liver transplantation is an important 
measure of burden from hepatitis C virus (HCV)-
associated liver disease. Aims: To describe transplant 
rates and survival in individuals with HCV infection 
from 2008 to 2017 in England through data linkage. 
Methods: This is a retrospective observational cohort 
study. Laboratory reports of HCV infection were linked 
to the Liver Transplant Registry for individuals aged 
15 years and over, first diagnosed between 1998 and 
2017. We estimated age-sex standardised incidence 
rates and used Poisson regression to investigate pre-
dictors of liver transplantation and test for a change 
in incidence after introduction of direct-acting antivi-
rals (DAAs) in 2014. Kaplan-Meier survival analysis 
was used to calculate post-transplant survival rates.
Results: Of 124,238 individuals diagnosed with HCV 
infection, 1,480 were registered and 1,217 received a 
liver transplant. Of individuals registered, 1,395 had 
post-HCV cirrhosis and 636 had hepatocellular carci-
noma (618 also had post-HCV cirrhosis). Median time 
from HCV diagnosis to transplant was 3.4 years (inter-
quartile range: 1.3–6.8 years). Liver transplant rates 
were lower 2014–17 compared with 2011–13 (incidence 
rate ratio: 0.64; 95% confidence interval: 0.55–0.76). 
Survival rates were 93.4%, 79.9% and 67.9% at 1, 5 
and 10 years, respectively. Data linkage showed mini-
mal under-reporting of HCV in the transplant registry.
Conclusion: In the post-DAA era, liver transplant rates 
have fallen in individuals with HCV infection, showing 
early impact of HCV treatment scale-up; but the short 
time from HCV diagnosis to liver transplant suggests 
late diagnosis is a problem.
Introduction
In 2018, around 113,000 individuals were estimated to 
be chronically infected with hepatitis C virus (HCV) in 
England [1]. These individuals are at increased risk of 
cirrhotic end-stage liver disease (ESLD) and hepatocel-
lular carcinoma (HCC), for which mortality rates had 
been increasing – doubling over 10 years from 2005 
to 2014 – until recent years [2]. Liver transplantation 
may be indicated if liver decompensation deteriorates. 
Between 2008 and 2014 in England, an average of 134 
individuals with post-HCV cirrhosis were registered for 
a liver transplant and 108 received a liver transplant 
each year, accounting for 17–21% of all liver trans-
plants [2].
HCV-related ESLD is preventable with early diagnosis 
and treatment of HCV infection, but historically esti-
mated treatment levels in the United Kingdom (UK) 
have been low (ca 3% annually) [3]. Low treatment 
rates have been attributed to: (i) interferon-based 
regimens which required injections, (ii) long treatment 
durations, (iii) poor tolerability and (iv) moderate effi-
cacy, as defined by a sustained virological response 
(SVR). In comparison, the newly introduced direct-
acting antivirals (DAAs) are taken orally, have short 
regimens and have SVRs that are above 95% [4]. Since 
2015, National Health Service (NHS) England has rolled 
out DAAs in a managed care programme with annual 
scale-up in treatment slots; an estimated 24,592 peo-
ple had been treated between the financial years of 
2015/16 and 2017/18 [5]. Widespread treatment with 
DAAs not only prevents the development of severe liver 
disease in individuals with HCV but can also improve 
liver function in individuals with advanced liver dis-
ease, which should contribute to a fall in the burden 
2 www.eurosurveillance.org
of HCV-associated disease and the need for liver trans-
plantation [4,6,7].
Since the expansion of treatment with DAAs in England, 
a 43% drop in the number of liver transplant registra-
tions has been recorded for individuals with post-HCV 
cirrhosis [2]. Vaziri et al. reported that the proportion 
of liver transplants attributed to HCV-associated cir-
rhosis fell from 10.5% to 4.7% between 2013 and 2016 
and the proportion of liver transplants for cancer-asso-
ciated HCV fell from 46.4% to 33.7% over the same 
period [8]. Similar results have been found in Italy, the 
United States (US) and Argentina [9-11]. A declining 
contribution of HCV-associated cirrhosis and cancer to 
transplants is helpful but is not a substitute for moni-
toring rates of HCV-associated transplants and may be 
limited by under-reporting of HCV coding in the liver 
transplant dataset, as has been observed in death reg-
istry data [12].
Through data linkage of routine laboratory reports of 
HCV and the NHS Blood and Transplant Service (NHSBT) 
liver transplant registry, we estimate liver transplant 
incidence rates and survival in the pre- (2008–13) 
and post-DAA (2014–17) eras, describe the character-
istics of individuals who are registered for and under-
went a liver transplant (2008–17) and explore any 
under-reporting of HCV in the transplant registry. We 
hypothesise that a reduction in transplant rates post 
introduction of DAAs will be observed, indicative of the 
early impact of DAA on HCV burden.
Methods
Using data linkage, we conducted a retrospective 
observational cohort study to describe the character-
istics of individuals diagnosed with HCV infection in 
England between 1998 and 2017, who were registered 
for and had received a liver transplant, and estimate 
liver transplant rates between 2008 and 2017.
Data sources
Routine laboratory reports of HCV infection
HCV diagnoses were obtained from routine laboratory 
reports of HCV, defined as the detection of HCV anti-
body (anti-HCV) or HCV RNA in blood, submitted by 
English virology laboratories to Public Health England 
(PHE). The laboratory surveillance system does not dis-
tinguish between anti-HCV or HCV RNA positive indi-
viduals, so laboratory ‘confirmed’ cases are a mix of 
current and ever infected individuals. Laboratory HCV 
reports have been submitted to PHE (and its predeces-
sor organisations) through paper forms or electroni-
cally since 1990 but laboratory reporting of notifiable 
organisms became mandatory in 2010. Reports include 
basic demographics (name, date of birth, sex and NHS 
number (a unique identifier for all individuals registered 
with the NHS within England)) and variable amounts of 
risk factor information (e.g. History of injecting drug 
use, testing within prison services, infection as a result 
of tattoos, piercings or blood products). Ethnicity is 
poorly recorded.
For this study, the routine laboratory reporting data-
set was enhanced with information from additional 
sources. As the date of the first HCV diagnosis is 
critical, this was updated with information from the 
Sentinel Surveillance of Blood Borne Virus Testing 
(SSBBV) and Hospital Episode Statistics (HES) when 
possible. Established in 2002, SSBBV collects informa-
tion on hepatitis A-E, HIV and HTLV tests (regardless 
of the result) from 23 participating sentinel laborato-
ries in England [13,14]. Earlier diagnosis dates were 
identified in HES where an earlier inpatient stay was 
recorded with HCV ICD-10 diagnosis codes (B17.1 and 
B18.2). HCV treatment with DAAs (date and outcome) 
was obtained through linkage with the national HCV 
treatment monitoring and outcomes dataset, estab-
lished in 2015. Date of death was obtained from the 
NHS Spine Patient Demographic Service.
Table 1
Characteristics of individuals diagnosed with hepatitis C 
virus, by transplantation status, England, 1998–2017
Characteristics HCV diagnoses Registered Transplanted
n % n %
Total 124,238 1,480 1.2 1,217 1.0
Sex
Male 84,444 1,170 1.4 959 1.1
Female 38,920 310 0.8 258 0.7
Not reported 874 0 0.0 0 0.0
Age (years)
15–29 24,231 23 0.1 20 0.1
30–39 40,398 172 0.4 138 0.3
40–49 31,711 578 1.8 474 1.5
≥ 50 27,688 707 2.6 585 2.1
Unknown 210 0 0.0 0 0.0
Year of Diagnosis
1998–02 17,124 464 2.7 392 2.3
2003–07 32,908 490 1.5 402 1.2
2008–12 36,648 406 1.1 320 0.9
2013–17 37,558 120 0.3 103 0.3
Region
East Midlands 6,833 43 0.6 35 0.5
East of England 9,940 213 2.1 185 1.9
London 27,103 317 1.2 268 1.0
North East 3,513 35 1.0 31 0.9
North West 24,454 215 0.9 151 0.6
South East 12,564 163 1.3 138 1.1
South West 13,366 138 1.0 114 0.9
West Midlands 11,129 201 1.8 171 1.5
Yorkshire and The 
Humber 15,248 155 1.0 124 0.8
Unknown 88 0.0 0.0 0.0 0.0
HCV: hepatitis C virus.
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Name, date of birth, sex and NHS number were used 
to de-duplicate reports. Information on individuals 
first diagnosed with HCV infection between 1998 and 
2017 with sufficient identifiers for linkage (name, sex, 
date of birth and NHS number) were extracted from the 
database.
National Transplant Database
Information on individuals registered for a liver trans-
plant in the National Transplant Database was obtained 
from NHSBT and included all liver transplant registra-
tions between 1994 and 2017, followed up to May 2018. 
The dataset contains basic demographics (date of birth, 
sex and ethnicity) of the recipient, liver disease at reg-
istration and transplant, results of pre-transplant HCV 
tests and outcome of registration. Additional clinical 
information for individuals who received a liver trans-
plant includes the UK Model for End-Stage Liver Disease 
(UKELD) score, encephalopathy grade and the presence 
of ascites and oesophageal varices. Registration on the 
transplant list can be considered elective (routine) or 
super-urgent (emergency). Outcome of registration 
includes: (i) still waiting for a transplant, (ii) transplant 
received, (iii) suspension from the registry (a tempo-
rary period of time during which a patient will not be 
considered for transplant e.g. if a patient was unfit or 
otherwise unavailable for transplant, (iv) death before 
transplant, and (v) removal from the registry if they no 
longer require a liver transplant. The transplant registry 
links with the Office for National Statistics (ONS) and 
is notified of the deaths of individuals who are on the 
waiting list, providing year and cause of death.
Data linkage
The two datasets were linked deterministically using 
a combination of name, date of birth, sex and NHS 
number.
Analysis
Age-sex standardised incidence rates (ASRs) of first 
liver transplant and first HCC-associated liver trans-
plant were calculated for individuals aged 15 years and 
older who were diagnosed with HCV infection between 
1998 and 2017 and are presented for 2008 to 2017. ASRs 
for 1998–2007 are not presented due to unstable rates 
and wide 95% confidence intervals (CI) (calculated 
using Poisson distribution) resulting from the smaller 
cohort size and limited follow-up time. Individuals who 
received a liver transplant before or within 6 months 
of HCV diagnosis were excluded from the analysis, as 
there was potential bias towards higher rates of diag-
nosis in individuals with major morbidity and in indi-
viduals who received a transplant before their reported 
HCV diagnosis were likely to have had a diagnosis prior 
to transplant which had not been reported to PHE. As 
a result, follow-up began 6 months after diagnosis and 
ended when the individual had a liver transplant, died 
or 31 December 2017 whichever occurred first. ASRs 
were also calculated for all liver transplants in England 
using ONS mid-year population estimates [15] and 
NHSBT data on all first liver transplants in England.
Table 2
Demographic and clinical characteristics of persons 
diagnosed with hepatitis C virus and registered for a 
liver transplant (n = 1,480) and received a liver transplant 
(n = 1,217), England, 1998–2017
Characteristics n %
Total registered for liver transplant 1,480 100
Sexa
Male 1,170 79.1
Female 310 20.9
Ethnicitya
White 1,159 78.3
Asian 240 16.2
Black 39 2.6
Other 42 2.8
Urgency of registrationa
Elective 1,464 98.9
Super urgent 16 1.1
Disease at registrationa,b
HCC 636 43.0
post-HCV cirrhosis 1,395 94.3
Alcoholic cirrhosis 383 25.9
Transplant outcome
Transplanted 1,217 82.2
Died 94 6.4
Removed from registry 166 11.2
Awaiting transplant 3 0.2
Total received a liver transplant 1,217 100
UKELD score at transplant
Median 52.5 (49–56)
Ascites at transplant
Yes 582 47.8
Encephalopathy grade at transplant
No encephalopathy 916 76.0
Grade 1 212 17.6
Grade 2 58 4.8
Grade 3 10 0.8
Grade 4 9 0.7
Not reported 12
Oesophageal varices at transplant
No previous variceal bleeding 417 35.0
Previous variceal bleeding 293 24.6
Not present 481 40.4
Not reported 26
Multiple liver transplants
2 79 6.5
3 3 0.2
HCC: hepatocellular carcinoma; HCV: hepatitis C virus; UKELD: 
United Kingdom Model for End-Stage Liver Disease.
a At registration for liver transplant.
b Three diseases at registration can be listed so some people may 
have been counted twice.
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Individuals were classified as having a record of HCV 
on the liver transplant registry if they had ‘post HCV 
cirrhosis’, a positive anti-HCV or positive HCV RNA test. 
Alcohol-associated comorbidities were recorded if liver 
disease at registration or transplant included ‘alcoholic 
cirrhosis’. Individuals were recorded as dead if they 
had a date or year of death in either dataset.
STATA SE version 13 (Stata Corp, College Station, Texas, 
US) was used for statistical analysis. Wilcoxon rank-
sum tests were used to compare continuous variables. 
Excluding individuals diagnosed with HCV following 
a liver transplant, Kaplan-Meier analysis was used to 
estimate the cumulative proportion of individuals hav-
ing had a liver transplant at 1, 5 and 10 years after HCV 
diagnosis. Poisson regression was used to identify 
predictors of receiving a liver transplant in individuals 
diagnosed with HCV between 1998 and 2016 and to test 
for a change in incidence pre and post 2014. Factors 
included in these models were sex, age at diagnosis 
and calendar year (grouped as 1998–2001, 2002–04, 
2005–07, 2008–10, 2011–13 and 2014–17). Individuals 
who received a liver transplant within 6 months of HCV 
diagnosis were excluded from this analysis and follow-
up was calculated in the same way as for the ASRs. 
Kaplan-Meier survival analysis was used to calculate 1, 
5 and 10-year post-transplant survival rates.
Ethical statement
The PHE Caldicott Guardian approved the collection 
and processing of confidential patient data, without 
patient consent, from routine laboratory reports of HCV 
infection, SSBBV and for linkage of these laboratory 
data to the liver transplant registry under Regulation 3 
of the Health Service (Control of Patient Information) 
Regulations 2002. Regulation 3 allows the processing 
of patient information for recognition, control and pre-
vention of communicable disease and other risks to 
public health.
Results
Of 161,820 individuals aged 15 years and older diag-
nosed with HCV in England between 1998 and 2017, 
124,238 (76.8%) had sufficient identifiers for linkage 
Figure 1
Age-sex standardised incidence rates by liver transplant and HCC-associated liver transplant in individuals diagnosed with 
hepatitis C virus between 1998–2017, and by all liver transplants in England, 2008 and 2017
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with the liver transplant registry. Where reported, 
84,444 (68.5%) of all individuals with HCV were male 
and the median age at report was 39 years (interquar-
tile range (IQR): 31–48 years) (Table 1). Of those with 
confirmed HCV, 1,480 (1.2%) were matched to the liver 
transplant registry and 15,282 (12.3%) had received 
HCV treatment with DAAs. The cumulative proportion 
of individuals who had received a liver transplant was 
0.2%, 0.7% and 1.1% at 1, 5 and 10 years after HCV 
diagnosis, respectively.
Transplant registry
Of 1,480 individuals registered for a liver transplant, 
79.1% were male and the median age at registration 
was 53 years (IQR 48–58 years) (Table 2). Among reg-
istrants, 94.3% had post-HCV cirrhosis, 43.0% had a 
record of HCC (618 of whom also had post-HCV cirrho-
sis), 1,187 (80.2%) had a positive HCV antibody or RNA 
test recorded on the liver transplant registry and 25.9% 
had a record of alcoholic cirrhosis. Only 47 (3.2%) of 
linked transplant registrants had no clinical indicators 
of a history of HCV infection (indicated by post-HCV cir-
rhosis or a positive HCV test).
As at July 2018, 1,217 of the 1,480 (82.2%) registered 
individuals had received a liver transplant; 13 trans-
plants were from living donors, 94 (6.4%) died before 
receiving a transplant, 116 (11.2%) were removed from 
the registry (including two who were suspended from 
the registry) and three (0.2%) remained on the registry 
on the follow-up date (Table 2). Persons who died while 
on the registry were on it for a median of 80 days (IQR: 
25–158 days).
Received a liver transplant
Of 1,217 individuals who received a transplant, the 
median age at transplant was 53 years (IQR 48–58) and 
individuals with a record of alcoholic cirrhosis were 
transplanted at a younger median age than those with 
no record of alcoholic cirrhosis (51 vs 54 years respec-
tively, p < 0.0001). Individuals waited for a median of 
75 days (IQR: 28–174 days) between registration and 
transplant and the majority (1,155; 94.9%) received 
their transplant after or on the same day as their HCV 
diagnosis in routine laboratory reporting (median: 3.4 
years; IQR: 1.3–6.8 years), while 66 individuals (5.1%) 
persons received a transplant before an HCV diagno-
sis in routine laboratory reporting (range: 1 day–20.0 
years). At time of the first transplant, the median UKELD 
score was 52.5 (IQR: 49–56), 47.8% had ascites and 
(where reported) the majority did not have encephalop-
athy (76.0%) or oesophageal varices (40.4%) (Table 2).
Age-sex standardised liver transplant incidence and 
HCC-associated liver transplant incidence between 
2008 and 2017 are presented in Figure 1. ASRs indicate 
that rates for both were stable between 2008 and 2014 
but fell between 2015 and 2017. Using Poisson regres-
sion, incidence rate ratios (IRR) for liver transplant 
were higher in males (IRR: 2.01; 95% CI: 1.73–2.34) and 
older persons at HCV diagnosis (per 10-year increase, 
IRR: 1.76; 95% CI: 1.69–1.83). When compared with 
2011–13, the IRRs for 1998–2001 and 2002–04 were 
higher (IRR: 2.42, 95% CI: 1.79–3.26 and IRR: 1.76, 95% 
CI: 1.40–2.21, respectively), rates for 2005–07 and 
2008–10 were similar (IRR: 0.83; 95% CI: 0.66–1.05 
and IRR: 1.07; 95% CI: 0.89–1.29, respectively) and 
rates for 2014–17 were lower (IRR: 0.64; 95% CI: 0.55–
0.76). These trends are in contrast to those seen ASRs 
in England as a whole (irrespective of HCV diagnosis 
and cause) which showed an increasing trend between 
2008 and 2017 (Figure 1).
Survival following a liver transplant
As at 30 May 2018, 348 (29.1%) of those who received 
a transplant had died, a median of 3.6 years after their 
first transplant (IQR 1.2–7.4 years). Where the cause of 
death was available (249/366; 71.6%), the most com-
mon cause of death was ‘multi-system failure’ (45; 
18.1%), followed by ‘other identified cause of death’ 
(31; 12.4%). Using the Kaplan-Meier method, unad-
justed survival rates following a liver transplant were 
93.4% (95% CI: 91.8–94.6), 79.9% (95% CI: 77.3–82.2) 
and 67.9% (95% CI: 64.5–71.1) at 1, 5 and 10 years 
(Figure 2).
Discussion
Among persons diagnosed with HCV between 1998 
and 2017, 1.2% were registered for a liver transplant, 
82.2% of whom received a transplant. Liver transplant 
rates were higher in males and in those who were older 
at HCV diagnosis and lower between 2014 and 2017, 
the post-DAA era, when compared with 2011–13. The 
majority of registrants had evidence of post-HCV cir-
rhosis and/or a record of HCC, with one in four hav-
ing a record of alcoholic cirrhosis. In individuals who 
received a transplant, the median time between HCV 
diagnosis and a transplant was 3.4 years and 69.7% of 
persons who received a transplant survived 10 years. 
Figure 2
Kaplan-Meier survival curve for individuals with hepatitis 
C virus infection who received a liver transplant, England, 
1998–2018
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Data linkage revealed that under-reporting of HCV 
diagnosis in the transplant registry was not a major 
concern.
Limitations
There are several limitations of this study. First, it is 
possible that individuals were diagnosed with HCV 
before PHE was notified or their diagnosis was not 
reported to PHE at all, thus impacting follow-up time. 
This would be more of an issue for individuals diag-
nosed before 2010, as since then, laboratories are 
legally required to notify PHE of all positive HCV tests. 
However, individuals, who were diagnosed before 2010 
(pre-legislation) may also have been tested with their 
HCV diagnosis reported post-2010 (post-legislation) 
and therefore captured in later years. Linkage with 
other surveillance systems can be used to update diag-
noses dates before 2010. Second, we did not have any 
information on whether individuals were acutely or 
chronically infected with HCV as this information can-
not be derived from the laboratory reports. However, 
as individuals with chronic infection are more likely 
to progress to advanced liver disease, we can assume 
that most individuals who were registered for a liver 
transplant had chronic hepatitis rather than acute ful-
minant hepatitis type presentation. Third, we had no 
information on the stage of liver disease at diagnosis 
in the HCV laboratory reports. This information would 
have been useful, as we found short time lag between 
HCV diagnosis and transplant registration, which we 
can only speculate is due to late diagnosis of liver 
disease and/or HCV when disease stage is already 
advanced. If the disease stage was available, we could 
have investigated liver transplant rates by disease 
stage at presentation.
Other evidence and implications
Through linked data, we identified a decline in HCV-
associated liver transplant rates after 2014, consist-
ent with unlinked published data for England [2,8] 
and internationally [9-11]. A separate study within the 
UK [8], using unlinked data, reported registered trans-
plants for patients with HCV-related cirrhosis fell from 
10.5% in 2013 to 4.7% in 2016. In Italy, a decrease 
was observed between pre-DAA and post-DAA periods 
for transplant waiting lists overall as well as among 
patients among those with decompensated cirrhosis, 
whereas figures associated with HCC remained stable 
[10]. A downward trend was identified in liver trans-
plants among patients with decompensated cirrhosis 
in Argentina [11]. A decline has also been reported in 
the US [9] among patients waiting for a transplant, with 
a lower likelihood of being on the waiting list in the DAA 
era compared with the pre-DAA era (Hazard Ratio 0.83). 
The decrease in liver transplant incidence in England 
among individuals with HCV within this study contrasts 
with the trend observed for all liver transplants, where 
rates have increased in recent years, albeit on a much 
smaller scale. It is encouraging to see a reduction in 
HCV-associated liver transplant rates and we hope 
that the incidence will continue to fall as case-finding 
activity increases helping to reduce the undiagnosed 
burden and ensuring that more individuals are treated 
with DAAs. A similar, although non-significant, decline 
has also been found in age-sex standardised liver mor-
tality rates among anti-HCV positive individuals [16].
Time from HCV diagnosis to transplant was short. 
Mindful of the established natural history of HCV infec-
tion causing liver disease progression over several 
decades [17], this indicates that this linked cohort of 
individuals with HCV was diagnosed late. As a result, 
individuals are likely to present with advanced liver 
disease, which is less amenable to HCV cure and may 
progress despite HCV cure. Poorer response rates to 
HCV treatment among patients with cirrhosis have 
been reported [18-20]. In an Italian study, the risk of 
failing SVR12 was 5.39 times higher among patients 
with decompensated cirrhosis and 1.56 times with 
compensated cirrhosis compared with those without 
cirrhosis [19]. In an American study, the efficacy was 
found to be significantly reduced to 73% and 91% 
among those with decompensated and compensated 
cirrhosis, respectively [20]. Two further studies, one 
European and Canadian-based and the other an Italian 
study, observed that the risk of liver disease continued 
among patients with cirrhosis despite SVR [21,22]. The 
linkage between SSBBV and the ONS death registry 
corroborate this finding, as the median time from HCV 
diagnosis to death (any cause) was 3 years [16]. While 
there are limited population-level data in England cur-
rently on disease stage at time of diagnosis of HCV, 
data from the national HCV treatment monitoring data-
set indicate that around 40% of individuals who have 
received treatment (2015–18) had moderate fibrosis to 
decompensated cirrhosis at the time of the decision 
to proceed with treatment. This is in part due to NHS 
England’s phased implementation of DAA treatments, 
prioritising patients with advanced cirrhosis and fibro-
sis before expanding treatment access to patients with 
milder disease.
Our results from the survival analysis following a trans-
plantation in an individual with an HCV diagnosis (1 
year: 93.4%; 5 years: 79.9%; 10 years: 67.9%) are simi-
lar to those found by Su Yin Lau et al. (1 year: 95.2%; 
5 years: 78.2%) and for all individuals who received 
a liver transplant in the UK (1 year: 93.4%; 5 years: 
80.5%) [23,24]. It is encouraging that survival following 
liver transplantation in individuals with HCV is similar 
to all persons receiving a liver transplant and that HCV 
does not appear to have an additive negative impact 
on survival rates.
It is important to note that under-reporting of HCV-
associated transplants is minimal, with only 3.2% of 
linked individuals having no record of HCV-associated 
disease or positive HCV tests in the transplant registry. 
This is much lower than the under-reporting with HCV-
associated mortality in England, where 41% of per-
sons who died of liver-related causes linked to an HCV 
laboratory diagnosis did not have HCV recorded as a 
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contributory cause in the deaths registry [12]. A similar 
level of under-reporting in mortality was also identified 
in the US [25] and Scotland [26], with 41% and 52% of 
individuals who died of liver-related causes, respec-
tively, having HCV indicated on their death certificate. 
The low level of under-reporting is important to quan-
tify as an accurate recording of HCV in transplant reg-
istry data reduces uncertainty in modelling to estimate 
prevalence and disease burden. These results improve 
confidence in the use of unlinked HCV-associated liver 
transplant data as a metric for monitoring progress 
towards elimination goals in England. Data linkage 
of HCV diagnoses to a transplant registry also offers 
an easily reproducible method for other European 
countries whose surveillance systems are limited by 
under-reporting of HCV diagnoses in transplant data-
bases and/or lack of information on long-term health 
outcomes in HCV laboratory diagnoses datasets. Data 
linkage also allows the burden of disease in the HCV 
diagnosed population, to be better understood and for 
an individual in this population to be followed from 
diagnosis to outcome. This is important when com-
paring this group to individuals who did not receive a 
transplant and for understanding these data in the con-
text of a country’s HCV epidemic. Liver transplantation, 
associated with chronic HCV infection, is an important 
measure of liver disease from HCV infection and coun-
tries may, therefore, choose to monitor this metric as 
an additional indicator (similar to HCV-related mortality 
and new chronic infections) of the impact of new DAA 
treatments and their contribution towards the WHO 
elimination goal [27].
Conclusion
By linking routinely collected datasets, we found 1.2% 
of persons with HCV were registered for a liver trans-
plant, with higher rates in males. The short median time 
from diagnosis to transplant suggests missed opportu-
nities for earlier diagnosis before irreversible liver dam-
age has occurred. Although based on early data, our 
analyses suggest that transplant rates have decreased 
further since 2014 (the year that DAAs became avail-
able in England). Efforts to reduce the undiagnosed 
HCV burden by active case finding, earlier diagno-
sis, improved engagement in care and expanded DAA 
treatment to people with mild or no fibrotic liver dis-
ease, could lead to sustained and potentially acceler-
ated reductions in HCV-associated liver transplants as 
progression to cirrhotic liver disease will become less 
common. Our study, therefore, provides a baseline 
from which to benchmark changes in HCV-associated 
transplant rates as part of evaluating the impact of 
DAAs and other interventions on eliminating HCV as a 
global public health threat by 2030.
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